Engineered virus-hunter vaccine overcomes HBV immune tolerance - Scorecard - MDSpire

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • By

  • Xiaoqing Chen

  • Xue Liu

  • Tao Xu

  • Yalin Wang

  • Peng Wang

  • Han Liu

  • Yichao Jiang

  • Xiaojing Qin

  • Liang Zhang

  • Yueting Xiong

  • Jiancheng Ding

  • Yuanzhi Chen

  • Fentian Chen

  • Wenjing Ning

  • Hongye Zeng

  • Shiting Yang

  • Lin Xu

  • Tianying Zhang

  • Quan Yuan

  • Chao Liu

  • Wenxin Luo

  • Ningshao Xia

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Vaccine Utilizing Engineered Virus-Hunting Mechanism Surmounts Immune Tolerance in HBV

At a Glance

CategoryDetail
ConditionChronic Hepatitis B Virus Infection
Key MechanismsIntegration of virus-clearance capacity with dendritic cell-targeted immunomodulation via SHARP.
Target PopulationPatients with chronic hepatitis B virus infection.
Care SettingClinical research and therapeutic development.

Key Highlights

  • SHARP combines antibody-mediated virus clearance with dendritic cell-targeted immunomodulation.
  • Stimulates strong virus-specific immune responses and persistent antiviral antibodies.
  • Establishes a new paradigm for antigen capture vaccines in HBV treatment.

Guideline-Based Recommendations

Diagnosis

  • Identify chronic hepatitis B virus infection through serological markers.

Management

  • Utilize SHARP for targeted immune activation and viral clearance.

Monitoring & Follow-up

  • Assess immune response and viral load post-treatment.

Risks

  • Monitor for potential systemic toxicity from immune-stimulatory agents.

Patient & Prescribing Data

Individuals with chronic hepatitis B virus infection.

SHARP may provide a functional cure by overcoming immune tolerance.

Clinical Best Practices

  • Target dendritic cells for enhanced antigen presentation.
  • Combine viral antigen delivery with immunomodulatory agents.

Related Resources & Content

Original Source(s)

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • by Xiaoqing Chen, Xue Liu, Tao Xu, Yalin Wang, Peng Wang, Han Liu, Yichao Jiang, Xiaojing Qin, Liang Zhang, Yueting Xiong, Jiancheng Ding, Yuanzhi Chen, Fentian Chen, Wenjing Ning, Hongye Zeng, Shiting Yang, Lin Xu, Tianying Zhang, Quan Yuan, Chao Liu, Wenxin Luo, Ningshao Xia

  • June 1, 2026

Related Content

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • by

  • June 1, 2026

  • 4 min
Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome

Existing and emerging strategies for fertility preservation in female patients with leukemia